Novartis reports data from Phase IIIb trial of SMA therapy

Swiss pharmaceutical company Novartis has reported new findings from the Phase IIIb SMART clinical trial, affirming the safety and efficacy of Zolgensma (onasemnogene abeparvovec) for treating spinal muscular atrophy (SMA).